Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9625482 | 0.90 | CHRM2 (0.63) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL19228128 | 0.85 | CHRM2 (0.55) | CHRM2DRD3ALDH1A1 | |
| SCHEMBL16715916 | 0.85 | CHRM2 (0.50) | CHRM2DRD3ALDH1A1MEN1CYP1A2 | |
| SCHEMBL3727196 | 0.83 | CHRM2 (0.56) | CHRM2ALDH1A1 | |
| SCHEMBL22784140 | 0.83 | CHRM2 (0.49) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL2599276 | 0.83 | CHRM2 (0.56) | CHRM2DRD3ALDH1A1MEN1CYP1A2 | |
| SCHEMBL5962347 | 0.82 | CHRM2 (0.54) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL469610 | 0.81 | CHRM2 (0.55) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL14481161 | 0.80 | CHRM2 (0.54) | CHRM2ALDH1A1 | |
| SCHEMBL14480981 | 0.80 | CHRM2 (0.54) | CHRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346822-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8735401-B2 | Thienopyrimidine compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | CHRM2 4653/4885DRD3 3234/4885ALDH1A1 153/4885 |
| US-20120071486-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | CHRM2 2439/4885DRD3 957/4885ALDH1A1 1567/4885 |
| US-20140221381-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | GNRHR, KISS1R, NR5A1 | CHRM2 2439/4885DRD3 957/4885ALDH1A1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.